Nisa Leung is a Managing Partner of Qiming Ventures leading its health care investments. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals Inc (acquired by SciClone NASDAQ: SCLN), a specialty pharmaceutical company focused on oncology and central nervous system and U-Systems Inc (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories, Novast Pharmaceuticals, Nurotron, Venus MedTech, Goodwill Information Technology, CanSino Biotechnology and Berry Genomics. Nisa oversees Qiming’s investments in Acea Biosciences, Aeonmed Medical, Alltech Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience, Origene Technologies, Richen, Shenogen, VR Medical and Wuxi Leiming.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is visiting lecturer at Harvard Law School, a founding member and Vice Chair of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Innovation Drug Investment Committee, director of Hong Kong Science and Technology Parks Corporation, council member of HKUST Business School and serves on the Board of Governors of the Hotchkiss School.